---
title: "Coya Therapeutics, Inc. (COYA.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/COYA.US.md"
symbol: "COYA.US"
name: "Coya Therapeutics, Inc."
industry: "生物技术"
---

# Coya Therapeutics, Inc. (COYA.US)

| Item | Detail |
|------|--------|
| Industry | 生物技术 |
| Location | 美股市场 |
| Website | [coyatherapeutics.com](https://coyatherapeutics.com) |

## Company Profile

Coya Therapeutics, Inc.是一家临床阶段的生物技术公司，开发专有疗法以增强调节性 T 细胞（Tregs）的功能。该公司的产品候选管线基于治疗性模式，如增强 Treg 功能的生物制剂、Treg 衍生的外泌体和自体 Treg 细胞疗法。它正在开发 COYA 302，这是一种用于皮下给药的生物制剂组合，旨在增强 Treg 功能，同时消耗 T 效应细胞功能和活化的巨噬细胞，目前正在进行针对肌萎缩侧索硬化症的二期临床试验，同时也用于前额叶痴呆、阿尔茨海默病（AD）和帕金森病。此外，该公司的临床前产品候选包括 COYA 301，一种低剂量白介素 2 产品候选，用于治疗 AD；COYA ...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-19T04:30:16.000Z

**Overall: D (0.71)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 280 / 399 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -58.26% |  |
| Net Profit YoY | -72.29% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 3.72 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 101.48M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 3.99M |  |


**Multi Score**: D

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -62.18% | E |
| Profit Margin | -462.25% | E |
| Gross Margin | 18.16% | D |

#### Growth Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -58.26% | E |
| Net Profit YoY | -72.29% | E |
| Total Assets YoY | -9.87% | E |
| Net Assets YoY | -14.76% | E |

#### Cash Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -21.63% | D |
| OCF YoY | -58.26% | E |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.12 | E |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 14.85% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Coya Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-62.18%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-462.25%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "18.16%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "E",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-58.26%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-72.29%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-9.87%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-14.76%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "E",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-21.63%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-58.26%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.12",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "14.85%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ADMA生物制药 (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | Rigel制药 (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -5.51 | 383/603 | - | - | - |
| PB | 3.72 | 263/603 | 3.89 | 3.40 | 2.84 |
| PS (TTM) | 25.45 | 206/603 | 227.50 | 28.71 | 24.92 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-18T05:00:00.000Z

Total Analysts: **7**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 7 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.85 |
| Highest Target | 18.00 |
| Lowest Target | 14.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/COYA.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/COYA.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/COYA.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.